Skip to main content

Table 1 Basal characteristics and biomarkers levels of patients with type 1 diabetes and control group

From: Relationship of YKL-40 and adiponectin and subclinical atherosclerosis in asymptomatic patients with type 1 diabetes mellitus from a European Mediterranean population

 

Type 1 diabetes

Control

p

N

150

50

 

Age (years)

38.6 ± 8.1

38.1 ± 7.2

NS

Sex (male/female %)

58/42

56/44

NS

Evolution type 1 diabetes (years)

20.4 ± 8.1

Family history CHD (%)

20

22

NS

Body mass index (kg/m2)

25.1 ± 3.6

25.3 ± 4.3

NS

Systolic blood pressure (mmHg)

117.3 ± 13.5

Diastolic blood pressure (mmHg)

70.9 ± 7.7

Retinopathy (%)

26

Nephropathy (%)

9

HbA1c (%, mmol/mol)

8.1 ± 2.3 (64.9 ± 11.4)

Total cholesterol (mg/dl)

182.7 ± 25.1

191.1 ± 34.1

NS

HDL (mg/dl)

60.3 ± 15.1

61.8 ± 16.6

NS

LDL (mg/dl)

105.3 ± 21.9

111.3 ± 33.5

NS

Smoke (% yes/no)

48/52

42/58

NS

Statins (%)

21

Antihypertensive (%)

15

Acetylsalicylic acid (%)

16

YKL-40 (ng/ml)

42.6 (10.4–195.0)

28.7 (11.0–51.2)

0.001

Adiponectin (mg/ml)

15.4 ± 8.4

11.9 ± 5.1

0.007

TNF-α (pg/ml)

7.5 ± 2.4

7.8 ± 1.8

NS

IL-1β (pg/ml)

1.0 ± 1.1

1.1 ± 0.8

NS

IL-6 (pg/ml)

2.0 ± 9.5

3.0 ± 4.0

NS

Homocysteine (mmol/l)

9.74 ± 5.1

10.9 ± 3.4

NS

hsCRP (mg/l)

2.21 ± 3,9

2.5 ± 3.9

NS